VCP
SRPT icon

Verus Capital Partners’s Sarepta Therapeutics SRPT Stock Holding History

Verus Capital Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$7K Hold
68
– – ﹤0.01% 1108
2019
Q4 		$9K Buy
+68
New +$6.86K ﹤0.01% 1181

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Verus Capital Partners's SRPT Position: Q1 2020 in Review

Verus Capital Partners held its Sarepta Therapeutics (SRPT) position steady in Q1 2020 at 68 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #1108.

Verus Capital Partners first reported a position in SRPT in Q4 2019 and has held it in 2 quarters since. The position peaked at $9K in Q4 2019. 365 funds tracked by Wall St. Rank hold SRPT as of Q1 2020.

  • Verus Capital Partners held 68 shares of Sarepta Therapeutics worth $7K as of Q1 2020.
  • Verus Capital Partners left its Sarepta Therapeutics share count unchanged in Q1 2020.
  • Sarepta Therapeutics made up ﹤0.01% of Verus Capital Partners's portfolio in Q1 2020, its #1108 holding.
  • Verus Capital Partners first reported a position in Sarepta Therapeutics in Q4 2019 and has held it in 2 quarters since.
  • Verus Capital Partners's Sarepta Therapeutics position peaked at $9K in Q4 2019.
  • 365 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2020.

Based on Verus Capital Partners's 13F filing for Q1 2020, filed 26 May 2020.